BRYOSTATIN IN RECURR OR PERSIST PLATINUM SENSITIVITY OVARIAN OR PERITONEAL CANCER

$42,739M01FY2000RRNIH

Tufts Medical Center, Boston MA

Investigators

Linked publications & trials

Paper 36732048 Paper 35728925 Paper 35005320 Paper 34401721 Paper 33478957 Paper 33305291 Paper 32807060 Paper 32634120 Paper 32446491 Paper 32111975 Paper 31874800 Paper 30775403 Paper 30737489 Paper 30631138 Paper 29872859 Paper 29854969 Paper 29564978 Paper 29537647 Paper 29306517 Paper 29203126 Paper 29118087 Paper 28460625 Paper 28279433 Paper 28199816 Paper 27993381 Paper 27677166 Paper 27642517 Paper 27484667 Paper 27423510 Paper 27074126 Paper 26823553 Paper 26354538 Paper 26231556 Paper 26080344 Paper 25500725 Paper 25399733 Paper 25399731 Paper 25317071 Paper 25047405 Paper 24861908 Paper 24418810 Paper 24378638 Paper 24370654 Paper 24225904 Paper 24183837 Paper 24136113 Paper 24067395 Paper 24054930 Paper 23784898 Paper 23567418 Paper 23494470 Paper 23353623 Paper 23076436 Paper 22926660 Paper 22909008 Paper 22748517 Paper 22739363 Paper 22362335 Paper 22319043 Paper 22307813 Paper 22239520 Paper 22205355 Paper 22073156 Paper 21926283 Paper 21903983 Paper 21897333 Paper 21767228 Paper 21748366 Paper 21572308 Paper 21543538 Paper 21521283 Paper 21508633 Paper 21480376 Paper 21396718 Paper 21311498 Paper 21310810 Paper 21292815 Paper 21285968 Paper 21130995 Paper 21059836 Paper 20928906 Paper 20829421 Paper 20709438 Paper 20679149 Paper 20679148 Paper 20671544 Paper 20647396 Paper 20581689 Paper 20539305 Paper 20502316 Paper 20495158 Paper 20335551 Paper 20309612 Paper 20218880 Paper 20141402 Paper 20104122 Paper 20100734 Paper 20089507 Paper 20009918 Paper 19935018

Abstract

This study will evaluate the efficacy and toxicity of bryostatin (two different types of regimens) in the treatment of patients with persistent or recurrent, platinum-sensitive ovarian cancer and primary peritoneal carcinoma. Our Goals Are: 1. To estimate the antitumor activity of bryostatin in patients with persistent or recurrent, platinum-sensitive ovarian cancer or primary peritoneal carcinoma who have failed on higher priority treatment protocols. 2. To determine the nature and degree of toxicity of bryostatin using two different schedules of administration (1 hour every week for 3 weeks followed by a one-week rest and 72 hours every two weeks) in this cohort of patients. 3. To obtain preliminary information on the pharmacokinetics and immunomodulatory effects of bryostatin.

View original record on NIH RePORTER →